Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial (updated)

Denali Therapeutics

16/02/2024 13:39

(Adds shares in paragraph 2 and details throughout)
       Feb 16 (Reuters) - Denali Therapeutics  DNLI.O  said on
Friday it was informed by partner Sanofi  SASY.PA  that their
drug for a type of neurological disease did not meet the main
goal in a mid-stage trial.
    Shares of Denali were down 6% in premarket trading.
    The companies were developing a drug to treat amyotrophic
lateral sclerosis (ALS), a rare neurological disease that can
break down nerve cells in the brain and spinal cord responsible
for muscle movements, leading to progressive paralysis and
death.
    Sanofi, however, will continue to conduct a mid-stage trial
evaluating the drug in participants with multiple sclerosis, a
disease of the central nervous system.
    Around 16,000 to 32,000 people have ALS in the United
States, according to government data.


 (Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
 ((Christy.Santhosh@thomsonreuters.com;))